Population PK-PD analyses of CD25 occupancy, CD56^bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis

详细信息    查看全文

• 作者：Lei Diao ; Yaming Hang ; Ahmed A. Othman ; Devangi Mehta ; Lakshmi Amaravadi ; Ivan Nestorov and Jonathan Q. Tran
• 刊名：British Journal of Clinical Pharmacology
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：82
• 期：5
• 页码：1333-1342
• 全文大小：591K
• ISSN：1365-2125

文摘

Daclizumab high yield process (HYP) is a humanized IgG1 monoclonal antibody that binds to the α-subunit of the interleukin-2 receptor and is being developed for treatment of multiple sclerosis (MS). This manuscript characterized the pharmacokinetic–pharmacodynamic (PK–PD) relationships of daclizumab HYP in subjects with MS.